According to DPI developer Iconovo, TOA Pharmaceutical has signed a new agreement for the use of an Iconovo dry powder inhaler for a feasibility study. TOA will pay €202,000 over the next year for use of the device in a development project for a generic aimed at the Japanese market. Iconovo did not specify which of its devices will be used in this new feasibility study.
TOA previously placed an order for modified versions of two Iconovo DPIs for use in a feasibility study In December 2018. The two companies had signed a letter of intent for development of DPIs for the Japanese market in December 2017.
Iconovo CEO Johan Wäborg said, “We are very happy to continue the collaboration between TOA and Iconovo that was started in 2017. The end goal is to enter a license agreement to develop an inhaled generic product to a pharmaceutical product with significant sales in the Japanese market based on an inhaler from Iconovo.”
Read the Iconovo press release.
